



Universiteit
Leiden
The Netherlands

The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis

Mackay, T.M.; Smits, F.J.; Roos, D.; Bonsing, B.A.; Bosscha, K.; Busch, O.R.; ... ; Dutch Pancreatic Canc Grp

Citation

Mackay, T. M., Smits, F. J., Roos, D., Bonsing, B. A., Bosscha, K., Busch, O. R., ... Besselink, M. G. (2020). The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. *Hpb*, 22(2), 233-240.

doi:10.1016/j.hpb.2019.06.019

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/3185336>

Note: To cite this publication please use the final published version (if applicable).

ORIGINAL ARTICLE

The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis

Tara M. Mackay¹, F. Jasmijn Smits², Daphne Roos³, Bert A. Bonsing⁴, Koop Bosscha⁵, Olivier R. Busch¹, Geert-Jan Creemers⁶, Ronald M. van Dam⁷, Casper H.J. van Eijck⁸, Michael F. Gerhards⁹, Jan Willem B. de Groot¹⁰, Bas Groot Koerkamp⁸, Nadia Haj Mohammad¹¹, Erwin van der Harst¹², Ignace H.J.T. de Hingh¹³, Marjolein Y.V. Homs¹⁴, Geert Kazemier¹⁵, Mike S.L. Liem¹⁶, Vincent E. de Meijer¹⁷, I. Quintus Molenaar¹¹, Vincent B. Nieuwenhuijs¹⁸, Hjalmar C. van Santvoort¹¹, George P. van der Schelling¹⁹, Martijn W.J. Stommel²⁰, Albert Jan ten Tije²¹, Judith de Vos-Geelen²², Fennie Wit²³, Johanna W. Wilmink²⁴, Hanneke W.M. van Laarhoven^{24,*}, Marc G. Besselink^{1*} on behalf of the Dutch Pancreatic Cancer Group

¹Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, ²Department of Surgery, University Medical Center Utrecht, Utrecht, ³Department of Surgery, Reinier de Graaf Group, Delft, ⁴Department of Surgery, Leiden University Medical Center, Leiden, ⁵Department of Surgery, Jeroen Bosch Hospital, Den Bosch, ⁶Department of Medical Oncology, Catharina Hospital, Eindhoven, ⁷Department of Surgery, Maastricht UMC+, Maastricht, ⁸Department of Surgery, Erasmus Medical Center, Rotterdam, ⁹Department of Surgery, OLVG, Amsterdam, ¹⁰Oncology Center Isala, Zwolle, ¹¹Department of Medical Oncology, Regional Academic Cancer Center Utrecht, University Medical Center Utrecht Cancer Center & St. Antonius Hospital Nieuwegein, ¹²Department of Surgery, Maasstad Hospital, Rotterdam, ¹³Department of Surgery, Catharina Hospital, Eindhoven, ¹⁴Department of Medical Oncology, Erasmus Medical Center, Rotterdam, ¹⁵Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, VU Medical Center, Amsterdam, ¹⁶Department of Surgery, Medisch Spectrum Twente, Enschede, ¹⁷Department of Surgery, University Medical Center Groningen, Groningen, ¹⁸Department of Surgery, Isala, Zwolle, ¹⁹Department of Surgery, Amphia Hospital, Breda, ²⁰Department of Surgery, Radboud UMC, Nijmegen, ²¹Department of Medical Oncology, Amphia Hospital, Breda, ²²Department of Internal Medicine, Division of Medical Oncology, GROW - School for Oncology and Developmental Biology, Maastricht UMC+, Maastricht, ²³Department of Surgery, Tjongerschans, Heerenveen, and ²⁴Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands

Abstract

Background: The relation between type of postoperative complication and not receiving chemotherapy after resection of pancreatic ductal adenocarcinoma (PDAC) is unclear. The aim was to investigate which patient factors and postoperative complications were associated with not receiving adjuvant chemotherapy.

Methods: Patients who underwent resection (2014–2017) for PDAC were identified from the nationwide mandatory Dutch Pancreatic Cancer Audit. The association between patient-, tumor-, center-, treatment characteristics, and the risk of not receiving adjuvant chemotherapy was analyzed with multivariable logistic regression.

Results: Overall, of 1306 patients, 24% (n = 312) developed postoperative Clavien Dindo ≥ 3 complications. In-hospital mortality was 3.5% (n = 46). Some 433 patients (33%) did not receive adjuvant chemotherapy. Independent predictors (all p < 0.050) for not receiving adjuvant chemotherapy were older age (odds ratio (OR) 0.96), higher ECOG performance status (OR 0.57), postoperative complications (OR 0.32), especially grade B/C pancreatic fistula (OR 0.51) and post-pancreatectomy hemorrhage (OR 0.36), poor tumor differentiation grade (OR 0.62), and annual center volume of <40 pancreatoduodenectomies (OR 0.51).

Conclusions: This study demonstrated that a third of patients do not receive chemotherapy after resection of PDAC. Next to higher age, worse performance status and lower annual surgical volume, this is mostly related to surgical complications, especially postoperative pancreatic fistula and post-pancreatectomy hemorrhage.

This paper is not based on a previous communication to a society or meeting.

* Shared senior authorship.

Received 20 May 2019; accepted 28 June 2019

Correspondence

Marc G. Besselink, Dept. of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, G4-146-1, 1105 AZ Amsterdam, the Netherlands. E-mail: m.g.besselink@amc.nl

Introduction

Adjuvant chemotherapy substantially improves survival and quality of life in patients undergoing resection of pancreatic ductal adenocarcinoma (PDAC) and is therefore the current standard of care for patients with a good performance status after resection.^{1,2} Several studies have shown that a substantial number of patients do not receive adjuvant treatment after pancreatic resection (range 24%–54%).^{3–6} These data are rather worrisome, especially since the recent French-Canadian PRODIGE-24 trial demonstrated an impressive 54 months overall survival with adjuvant modified FOLFIRINOX as compared to 35 months with adjuvant gemcitabine.¹

Whether adjuvant chemotherapy is given depends on patient, doctor, and hospital factors. With respect to patient factors, postoperative complications are important. Several small retrospective studies have suggested an association between complications after pancreatic resection and delay or omission of adjuvant chemotherapy.^{4,6–10} Larger studies either investigated only one specific complication (e.g., pancreatic fistula), or are relatively outdated, especially since the quality and efficiency of both perioperative care and adjuvant therapy has improved.^{4,11,12} Large, observational studies on the impact of patient factors, hospital factors and postoperative complications on the risk of not receiving adjuvant chemotherapy are lacking.

The aim of this study, which used data from a nationwide mandatory prospective surgical audit, was to investigate which patient factors, hospital factors and postoperative complications are associated with not receiving adjuvant chemotherapy after resection of PDAC.

Methods

Study design

This was a nationwide analysis of prospectively collected data within the Dutch Pancreatic Cancer Audit (DPCA).^{13,14} All Dutch patients with PDAC who underwent resection in the period 2014–2017 in 19 centers were included. One center stopped pancreatic surgery after 2015 and two centers merged, leaving 17 centers at the end of the study period. Patients were divided into subgroups of (A) no or minor complications (Clavien Dindo <3) and (B) major complications (Clavien Dindo ≥3).¹⁵ Patients with more than one complication were categorized according to their most severe complication. Patients

were excluded if data on postoperative complications or on adjuvant chemotherapy were missing. This study was designed in accordance with the STROBE guidelines.

Data collection

Data were retrieved from the DPCA database, including patient characteristics (i.e. age at resection, sex, preoperative ECOG performance status, ASA score, and comorbidities), tumor characteristics (i.e. resection margins, T-stage, N-stage, and tumor differentiation grade), treatment characteristics (i.e. neoadjuvant chemotherapy, surgical procedure, and minimally invasive surgery), length of hospital stay, postoperative complications (i.e. general and pancreatic surgery specific complications), in-hospital mortality, the use of adjuvant chemotherapy, and interval between resection and start of adjuvant chemotherapy. General complications were pneumonia (diagnosed with X-ray), wound infection (requiring at least opening, flushing and covering of the wound with gauze), organ failure (dialysis, inotropes, and/or artificial respiration required), and death. Pancreatic surgery specific complications (only grade B and C) included postoperative pancreatic fistula, delayed gastric emptying, bile leakage, post pancreatectomy hemorrhage, and chyle leakage, all of which defined according to the International Study Group on Pancreatic Surgery (ISGPS).^{16–21} Data on pancreatic fistula and chyle leakage according to ISGPS 2016 definitions were only available for 2017. Tumor stage was defined in accordance with the 7th TNM classification edition. Margin status was classified as microscopically radical resection (>1 mm; R0) and microscopically irradical resection (≤1 mm; R1). Time to adjuvant chemotherapy was defined as time between pancreatic resection and start date of chemotherapy. To assess the accuracy of data on adjuvant chemotherapy in the DPCA, validation was performed through the Netherlands Cancer Registration, an independent population-based registry collecting data on all patients with cancer in the Netherlands. The percentage of resected PDAC patients receiving adjuvant chemotherapy was compared between both registries. A 96% concordance was found for the years 2013–2015.

Centers participating in the DPCA were classified into 2 groups based on the mean annual pancreatoduodenectomy (PD) volume (regardless of the indication for resection) according to predefined groups²²: medium (<40 PDs) and high (≥40 PDs) volume centers.

Table 1 Characteristics of 1306 Dutch patients with resected PDAC (2014–2017)

Age at resection ($\pm$ SD)	67 ($\pm$ 9.5)
BMI ($\pm$ SD)	24.9 ($\pm$ 4.1)
Sex (male)	719 (55.1%)
ECOG performance status	
0	588 (45.0%)
I	542 (41.5%)
II	121 (9.3%)
III	20 (1.5%)
IV	34 (2.6%)
ASA score	
I	165 (12.6%)
II	837 (64.1%)
III	299 (22.9%)
IV	5 (0.4%)
Comorbidity	
Cardiovascular	608 (46.6%)
Pulmonary	165 (12.6%)
Renal	127 (9.7%)
Hepatic	16 (1.2%)
Neoadjuvant chemotherapy (received)	111 (8.5%)
Surgical procedure	
Pancreatoduodenectomy ^a	1067 (81.7%)
Distal pancreatectomy	188 (14.4%)
Central pancreatectomy	1 (0.1%)
Total pancreatectomy	44 (3.4%)
Other	6 (0.5%)
Minimally invasive surgery ^b	211 (16.2%)
Pancreatoduodenectomy volume	
Medium (<40)	716 (54.8%)
High ($\geq$ 40)	590 (45.2%)
Microscopic resection margins	
R0	783 (60.0%)
R1	523 (40.0%)
T stage	
T1	67 (5.1%)
T2	151 (11.6%)
T3	1033 (79.1%)
T4	55 (4.2%)
N stage	
N0	403 (30.9%)
N1	903 (69.1%)
Tumor differentiation grade	
Well	161 (12.3%)
Moderate	729 (55.8%)

Table 1 (continued)

Poor	356 (27.3%)
Undifferentiated	60 (4.6%)
Adjuvant chemotherapy (not received)	433 (33.2%)
Median time to adjuvant chemotherapy in days (IQR) ^c	48 (37–62) (n = 380)

^a Whipple, pylorus preserving and pylorus resecting pancreatoduodenectomy.

^b Including procedures with conversion to open surgery (n = 214, 25.7%).

^c Patients excluded that died during initial hospital admission (n = 46, 3.5%).

Statistical analysis

Baseline characteristics and outcomes were assessed using descriptive statistics. Categorical variables were reported as proportions. Parametric continuous variables were reported as mean with standard deviation (SD) and non-parametric continuous variables as median with interquartile range (IQR). Missing data (range 0.6–13.2%) were imputed by multiple imputation techniques in which 10 dummy sets were created.

Patient and tumor characteristics, as well as treatment and surgical outcome parameters were assessed with univariable analysis as potential predictors for not receiving adjuvant chemotherapy. Variables with $p < 0.10$ were subsequently selected for multivariable logistic regression analysis with backward stepwise selection and reported as odds ratio (OR) with corresponding 95% confidence interval (CI). A subgroup analysis was performed in which the effect of individual complications on not receiving chemotherapy was evaluated, when adjusted for other previously identified confounders. Sensitivity analyses were performed excluding (i) patients who received neoadjuvant chemotherapy (n = 111) and (ii) patients with in-hospital mortality (n = 46). All p-values were based on a 2-sided test. A p-value of below 0.05 was considered statistically significant. Statistical analyses were performed in SPSS Statistics version 24 and R version 3.4.4.

Results

Study population

In total, 1457 patients underwent a resection for PDAC between 2014 and 2017. After exclusion of patients with missing data on postoperative complications (n = 29, 2.0%) or on adjuvant chemotherapy (n = 122, 8.4%), the final cohort consisted of 1306 patients. Patient, tumor and treatment characteristics are given in Table 1.

Adjuvant chemotherapy and postoperative complications

The in-hospital mortality was 3.5% (n = 46/1306). Overall, 427 patients (32.7%) suffered from minor complications and 312

(23.9%) from major complications. A total of 873 patients (66.8% of the total cohort and 69.3% after exclusion of patients with in-hospital mortality) received adjuvant chemotherapy, of whom 848 (97.1%) received only chemotherapy and 25 (2.9%) received a combination of chemotherapy and radiotherapy.

The proportion of patients who did not receive adjuvant chemotherapy differed significantly between centers during the study period (range 11.9%–68.3%, $p < 0.001$, Fig. 1) and varied from 39.9% in medium volume to 25.1% in high volume centers respectively ($p < 0.001$).

Patients with major complications less frequently received adjuvant chemotherapy, as compared with patients with minor or no complications (51.6% vs. 27.4%, $p < 0.001$). Overall, median time to commence adjuvant chemotherapy was 48 days (IQR 37–62) after resection, and was significantly longer for patients with major versus minor or no complications (56 vs. 47 days, $p < 0.001$).

The univariable and multivariable analyses of factors that predict not receiving adjuvant chemotherapy are shown in Table 2.

Table 3 summarizes the sub-analysis of the association of specific complications with not receiving adjuvant chemotherapy. After sensitivity analyses, excluding 111 patients who received neoadjuvant chemotherapy, results remained similar (Supplementary Tables S1 and S2). After sensitivity analyses, excluding 46 patients with in-hospital mortality, results remained similar (Supplementary Tables S3 and S4).

Of the 305 patients with ECOG 0 or 1 performance status and age < 70 years who underwent surgery in high volume centers, 57 (18.8%) did not receive adjuvant chemotherapy; 45 (14.7%) developed minor or no complications versus 95 (31.1%) who developed major complications ($p = 0.003$). The risk of not

receiving adjuvant chemotherapy in this ‘best-case-scenario’ was still high for patients with major complications (OR 0.38, 95% CI 0.21–0.70, $p = 0.002$).

Discussion

This nationwide multicenter study demonstrated that a third of patients did not receive adjuvant chemotherapy after resection of PDAC, with considerable variation among centers. Postoperative surgical complications, especially pancreatic fistula and post-pancreatectomy hemorrhage, were the strongest predictor for not receiving adjuvant chemotherapy, followed by increased age and a lower annual center volume.

Reported rates of not receiving adjuvant chemotherapy range from 26% to 54% in previous population-based studies,^{3,4,6} and was 33% in this study. In this cohort, 24% of patients suffered from major postoperative complications. Previous studies report similar complication rates.^{4,6,9,10,12,23} The odds of receiving adjuvant chemotherapy decreased significantly in these patients (OR 0.32, 95% CI 0.24–0.42). Patients suffering from postoperative complications, specifically pancreatic fistula and post-pancreatectomy hemorrhage, may have a performance status which is too poor to start adjuvant chemotherapy within the advocated three months after surgery.^{24,25} Similar results have been found for adjuvant treatment after surgery for colon and gastric cancer.^{26–28} In addition, a recent Dutch study showed that pancreatic centers differed little in the incidence of postoperative complications, but that centers of excellence had much better ‘failure to rescue rates’ from these complications.²⁹ This emphasizes the importance of prevention but also early detection and adequate management of postoperative complications, especially pancreatic fistula.^{30,31} To improve




Figure 1 Proportion of patients after surgical resection of PDAC who did not receive adjuvant chemotherapy per Dutch center between 2014 and 2017

Table 2 Uni- and multivariable logistic regression for the risk not receiving adjuvant chemotherapy after surgical resection for PDAC in a nationwide cohort

	Univariable		Multivariable	
	OR (95% CI)	p-value	OR (95% CI)	p-value
<i>Age at resection</i>	0.95 (0.94–0.97)	<0.001	0.96 (0.94–0.97)	<0.001
<i>ECOG performance status</i>				
0–I	Ref		Ref	
II–IV	0.53 (0.38–0.74)	<0.001	0.57 (0.39–0.83)	0.003
<i>ASA score</i>				
I	Ref			
II	0.76 (0.52–1.12)	0.172		
III–IV	0.40 (0.26–0.61)	<0.001		
<i>Comorbidity</i>				
Cardiovascular	0.67 (0.53–0.85)	0.001		
Pulmonary	0.71 (0.51–1.00)	0.056		
Renal	0.60 (0.41–0.88)	0.081		
Hepatic	0.72 (0.24–2.14)	0.558		
<i>Neoadjuvant chemotherapy</i>	1.49 (0.93–2.40)	0.090		
<i>Surgical procedure</i>				
Pancreatoduodenectomy ^a	Ref			
Distal pancreatectomy	0.83 (0.60–1.14)	0.254		
Central pancreatectomy ^b	–	–		
Total pancreatectomy	0.62 (0.39–1.00)	0.133		
Other	0.47 (0.21–1.07)	0.369		
<i>Annual volume of pancreatoduodenectomy</i>				
Medium (<40)	0.51 (0.40–0.65)	<0.001	0.51 (0.39–0.66)	<0.001
High (≥40)	Ref		Ref	
<i>Microscopic resection margins</i>				
R0	Ref			
R1	0.99 (0.78–1.27)	0.971		
<i>T stage</i>				
T1	Ref			
T2	1.10 (0.59–2.05)	0.783		
T3	1.23 (0.72–2.11)	0.452		
T4	0.63 (0.30–1.34)	0.224		
<i>N stage</i>				
N0	Ref			
N1	1.21 (0.95–1.55)	0.130		
<i>Tumor differentiation grade</i>				
Well	Ref		Ref	
Moderate	0.90 (0.61–1.32)	0.584	0.90 (0.59–1.40)	0.612
Poor	0.68 (0.43–0.99)	0.040	0.62 (0.39–0.98)	0.041
Undifferentiated	0.88 (0.33–2.36)	0.797	0.96 (0.32–2.88)	0.944
<i>Postoperative complications</i>				
None or minor	Ref		Ref	
Major	0.35 (0.27–0.46)	<0.001	0.32 (0.24–0.42)	<0.001

Bold in univariable analysis indicates variables ($p < 0.10$) that were entered in multivariable analysis. Bold in multivariable analysis indicates statistical significance ($p < 0.05$).

^a Whipple, pylorus preserving and pylorus resecting pancreatoduodenectomy.

^b Not enough events for statistical analysis.

Table 3 Uni- and multivariable analysis for the association between the various individual complications with adjuvant chemotherapy after surgical resection for PDAC

	Univariable		Multivariable	
	OR (95% CI)	p-value	OR (95% CI) ^a	p-value
<i>Pancreatic fistula (ISGPS 2005)</i>				
None or grade A	Ref		Ref	
Grade B/C	0.46 (0.31–0.68)	<0.001	0.51 (0.33–0.79)	0.003
<i>Pancreatic fistula (ISGPS 2016)</i>				
None or biochemical leak	Ref			
Grade B/C	0.48 (0.23–0.99)	0.050		
<i>Delayed gastric emptying</i>				
None or grade A	Ref			
Grade B/C	0.79 (0.57–1.11)	0.173		
<i>Bile leakage</i>				
None or grade A	Ref			
Grade B/C	0.45 (0.22–0.92)	0.038		
<i>Post-pancreatectomy hemorrhage</i>				
None or grade A	Ref		Ref	
Grade B/C	0.35 (0.22–0.55)	<0.001	0.36 (0.22–0.59)	<0.001
<i>Chyle leakage</i>				
None or grade A	Ref			
Grade B/C	0.68 (0.31–1.51)	0.344		
<i>Pneumonia</i>				
No	Ref			
Yes	0.39 (0.20–0.75)	0.013		
<i>Surgical site infection</i>				
No	Ref			
Yes	0.81 (0.48–1.39)	0.455		
<i>Atrial fibrillation</i>				
No	Ref			
Yes	0.42 (0.18–1.01)	0.057		

Bold in univariable analysis indicates variables ($p < 0.10$) that were entered in multivariable analysis. Bold in multivariable analysis indicates statistical significance ($p < 0.05$).

^a Analysis adjusted for age at resection, ECOG performance status, pancreatoduodenectomy volume and tumor differentiation grade.

postoperative complication management and subsequent oncological care in pancreatic cancer, two nationwide randomized stepped-wedge trials, PORSCHE (NCT03400280) and PACAP-1 (NCT03513705) were recently launched in the Netherlands.

Increased age at the time of resection, poor ECOG performance status and poor tumor differentiation grade were independent predictors for not receiving adjuvant chemotherapy and may influence the decision of clinicians and patients to pursue upfront surgery followed by adjuvant treatment. Increased age is a known risk factor for not receiving adjuvant chemotherapy in PDAC^{7,8,10,24,32} and other types of cancer.^{26–28} Previous studies on adjuvant treatment have not investigated the influence of ECOG performance status in

PDAC, but this relationship was previously described in colorectal cancer.³³

Although tumor differentiation grade should not influence the administration of adjuvant treatment after PDAC resection, poor differentiation grade was an independent risk factor for not receiving adjuvant chemotherapy. This finding is different from previous studies that suggest higher willingness of clinicians to administer adjuvant chemotherapy to patients with worse prognosis PDAC (e.g. higher T-stage).^{24,32} However, specifically for cancers with a poor prognosis, such as PDAC, oncologists may be pessimistic about the added value of adjuvant treatment, especially when predictors for worse outcomes such as poor differentiation grade are present. With the introduction of newer and more effective chemotherapy regimens such as

FOLFIRINOX with a clear survival benefit compared to gemcitabine (median overall survival 54 vs. 35 months),¹ it may be speculated that in the future more patients with PDAC will be treated with adjuvant chemotherapy, even if negative outcome predictors are present. Nevertheless, it should be noted that implementation of improvements in daily medical care are inherently slow, underlining the relevance of bringing to attention the thus far limited uptake of adjuvant chemotherapy after pancreatic resection.

Adjuvant chemotherapy was administered more often in patients who underwent pancreatic resection in a high volume as compared to a medium volume center (40% vs. 25%). Volume-outcome relationships have clearly been established for surgical outcome after PD for cancer.^{22,29,34} A previous study showed that center volume is also relevant for palliative chemotherapy for metastatic PDAC.³⁵ The current study results suggest that institutional volume may also be relevant for adjuvant chemotherapy. Oncologists from high volume centers may be more willing to administer systemic treatment to a broader selection of patients. It may also be possible that more motivated patients who are willing to undergo chemotherapy are more likely to visit high volume centers for treatment.

Neoadjuvant chemotherapy for patients with PDAC is currently gaining popularity and several studies have shown a survival benefit compared to adjuvant therapy.^{36–38} Some have argued that neoadjuvant treatment may improve the use of systemic treatment, as this treatment strategy avoids the issue of postoperative complications, as treatment is given prior to surgery. Neoadjuvant treatment may also improve R0-resection rates compared to upfront surgery for (borderline) resectable PDAC.^{36–38} To assess the effect of neoadjuvant FOLFIRINOX in patients with (borderline) resectable PDAC, the PREOPANC-2 trial (NTR7292) was recently launched in the Netherlands. Neoadjuvant treatment in the Netherlands is only given in trial settings, as the current standard of care is adjuvant chemotherapy.

This study has several limitations. First, the nationwide DPCA does not collect data on type of chemotherapy, side effects, dose reductions, completion of treatment, or long-term survival. Second, the DPCA may not collect data from patients referred to another hospital for adjuvant chemotherapy correctly. Cross-validation with the Netherlands Cancer Registry data, however, showed a 96% concordance. Therefore, the impact of this bias is probably small. The strength of the current study is that the participation in the DPCA is mandatory and contains data on all pancreatic resections in the Netherlands.

In conclusion, increased age at resection, worse ECOG performance status, poor tumor differentiation, annual center volume of <40 PDs, but mostly major postoperative complications are independently associated with not receiving adjuvant chemotherapy after resection of PDAC. Pancreatic fistula and post-pancreatectomy hemorrhage were the strongest predictors for not receiving adjuvant chemotherapy.

These findings may further fuel the current debate of the value of neoadjuvant versus adjuvant treatment strategies in PDAC.

Acknowledgements

The Dutch Pancreatic Cancer Project, including the Dutch Pancreatic Cancer Audit, received funding from the Dutch Cancer Society (KWF Kankerbestrijding; grant no. UVA2013-5842).

We thank Elizabeth M. Gleeson, MD, MPH, for proofreading of the manuscript.

Conflicts of interest

None declared.

References

- Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L et al. (2018) FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. *N Engl J Med* 379:2395–2406.
- Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM et al. (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. *Lancet (Lond, Engl)* 389:1011–1024.
- Burmeister EA, O'Connell DL, Beesley VL, Goldstein D, Gooden HM, Janda M et al. (2015) Describing patterns of care in pancreatic cancer: a population-based study. *Pancreas* 44:1259–1265.
- Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS et al. (2014) Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. *Ann Surg* 260:372–377.
- Van Rijssen LB, van der Geest LG, Bollen TL, Bruno MJ, van der Gaast A, Veerbeek L et al. (2016) National compliance to an evidence-based multidisciplinary guideline on pancreatic and periampullary carcinoma. *Pancreatology – Offic J Int Assoc Pancreatol (IAP)* 16:133–137.
- Watanabe Y, Nishihara K, Matsumoto S, Okayama T, Abe Y, Nakano T. (2017) Effect of postoperative major complications on prognosis after pancreatectomy for pancreatic cancer: a retrospective review. *Surg Today* 47:555–567.
- Akerberg D, Björnsson B, Ansari D. (2017) Factors influencing receipt of adjuvant chemotherapy after surgery for pancreatic cancer: a two-center retrospective cohort study. *Scand J Gastroenterol* 52:56–60.
- Labori KJ, Katz MH, Tzeng CW, Bjornbeth BA, Cvancarova M, Edwin B et al. (2016) Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma – a population-based cohort study. *Acta Oncol (Stockh, Swed)* 55:265–277.
- Le AT, Huang B, Hnoosh D, Saeed H, Dineen SP, Hosein PJ et al. (2017) Effect of complications on oncologic outcomes after pancreaticoduodenectomy for pancreatic cancer. *J Surg Res* 214:1–8.
- Wu W, He J, Cameron JL, Makary M, Soares K, Ahuja N et al. (2014) The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. *Ann Surg Oncol* 21:2873–2881.
- Cameron JL, Riall TS, Coleman J, Belcher KA. (2006) One thousand consecutive pancreaticoduodenectomies. *Ann Surg* 244:10–15.
- Kawai M, Murakami Y, Motoi F, Sho M, Satoi S, Matsumoto I et al. (2016) Grade B pancreatic fistulas do not affect survival after

- pancreatectomy for pancreatic cancer: a multicenter observational study. *Surgery* 160:293–305.
13. Coebergh van den Braak RRRJ, van Rijssen LB, van Kleef JJ, Vink GR, Berbee M, van Berge Henegouwen MI *et al.* (2018) Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative. *Acta Oncol (Stockh, Swed)* 57:195–202.
 14. Van Rijssen LB, Koerkamp BG, Zwart MJ, Bonsing BA, Bosscha K, van Dam RM *et al.* (2017) Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. *HPB – Offic J Int Hepato Pancreato Biliary Assoc* 19:919–926.
 15. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD *et al.* (2009) The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg* 250:187–196.
 16. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M *et al.* (2017) The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years after. *Surgery* 161:584–591.
 17. Besselink MG, van Rijssen LB, Bassi C, Dervenis C, Montorsi M, Adham M *et al.* (2017) Definition and classification of chyle leak after pancreatic operation: a consensus statement by the International Study Group on Pancreatic Surgery. *Surgery* 161:365–372.
 18. Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L *et al.* (2011) Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. *Surgery* 149:680–688.
 19. Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR *et al.* (2007) Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). *Surgery* 142:761–768.
 20. Wente MN, Veit JA, Bassi C, Dervenis C, Fingerhut A, Gouma DJ *et al.* (2007) Postpancreatectomy hemorrhage (PPH): an international study group of pancreatic surgery (ISGPS) definition. *Surgery* 142:20–25.
 21. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J *et al.* (2005) Postoperative pancreatic fistula: an international study group (ISGPF) definition. *Surgery* 138:8–13.
 22. van der Geest LG, van Rijssen LB, Molenaar IQ, de Hingh IH, Koerkamp BG, Busch OR *et al.* (2016) Volume-outcome relationships in pancreatoduodenectomy for cancer. *HPB – Offic J Int Hepato Pancreato Biliary Assoc* 18:317–324.
 23. Kneuzt PJ, Pitt HA, Bilimoria KY, Smiley JP, Cohen ME, Ko CY *et al.* (2012) Risk of morbidity and mortality following hepato-pancreato-biliary surgery. *J Gastrointest Surg – Offic J Soc Surg Aliment Tract* 16:1727–1735.
 24. Bakens MJ, van der Geest LG, van Putten M, van Laarhoven HW, Creemers GJ, Besselink MG *et al.* (2016) The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis. *Cancer Med* 5:2825–2831.
 25. Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P *et al.* (2014) Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. *J Clin Oncol – Offic J Am Soc Clin Oncol* 32:504–512.
 26. Bos AC, van Erning FN, van Gestel YR, Creemers GJ, Punt CJ, Van Oijen MG *et al.* (2015) Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. *Eur J Cancer (Oxford, England: 1990)* 51:2553–2561.
 27. Schouwenburg MG, Busweiler LA, Beck N, Henneman D, Amodio S, van Berge Henegouwen MI *et al.* (2018 Apr) Hospital variation and the impact of postoperative complications on the use of perioperative chemo(radio)therapy in resectable gastric cancer. Results from the Dutch Upper GI Cancer Audit. *Eur J Surg Oncol* 44:532–538. <https://doi.org/10.1016/j.ejso.2018.01.008>. Epub 2018 Jan 12.
 28. Van der Geest LG, Portielje JE, Wouters MW, Weijl NI, Tanis BC, Tollenaar RA *et al.* (2013) Complicated postoperative recovery increases omission, delay and discontinuation of adjuvant chemotherapy in patients with Stage III colon cancer. *Colorectal Dis – Offic J Assoc Coloproctol Gt Brit Irel* 15:e582–e591.
 29. van Rijssen LB, Zwart MJ, Van Dieren S, de Rooij T, Bonsing BA, Bosscha K *et al.* (2018 Aug) Variation in hospital mortality after pancreatoduodenectomy is related to failure to rescue rather than major complications: a nationwide audit. *HPB (Oxford)* 20:759–767. <https://doi.org/10.1016/j.hpb.2018.02.640>. Epub 2018 Mar 21.
 30. Mezhir JJ. (2013) Management of complications following pancreatic resection: an evidence-based approach. *J Surg Oncol* 107:58–66.
 31. Villafane-Ferriol N, Shah RM, Mohammed S, George Van Buren II, Barakat O, Massarweh NN *et al.* (2018) Evidence-based management of drains following pancreatic resection: a systematic review. *Pancreas* 47:12–17.
 32. Nussbaum DP, Adam MA, Youngwirth LM, Ganapathi AM, Roman SA, Tyler DS *et al.* (2016) Minimally invasive pancreaticoduodenectomy does not improve use or time to initiation of adjuvant chemotherapy for patients with pancreatic adenocarcinoma. *Ann Surg Oncol* 23:1026–1033.
 33. Ahmed S, Pahwa P, Fields A, Chandra-Kanthan S, Iqbal N, Zaidi A *et al.* (2015) Predictive factors of the use of systemic therapy in stage IV colorectal cancer: who gets chemotherapy? *Oncology* 88:289–297.
 34. Finks JF, Osborne NH, Birkmeyer JD. (2011) Trends in hospital volume and operative mortality for high-risk surgery. *N Engl J Med* 364:2128–2137.
 35. Mohammad NH, Bernards N, Besselink MG, Busch OR, Wilmink JW, Creemers GJ *et al.* (2016) Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in The Netherlands. *J Cancer Res Clin Oncol* 142:1353–1360.
 36. Van Tienhoven G, Versteijne E, Suker M, Groothuis KB, Busch OR, Bonsing BA *et al.* (2018) Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): a randomized, controlled, multicenter phase III trial. *J Clin Oncol* 36 (suppl; abstr LBA4002). 2018.
 37. Versteijne E, Vogel JA, Besselink MG, Busch OR, Wilmink JW, Daams JG *et al.* (2018) Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. *Br J Surg* 105:946–958.
 38. Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH *et al.* (2018) Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. *Ann Surg* 268:215–222.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.hpb.2019.06.019>.